Skip to content
PharmaManufacturingIQ

Inhaled Biologics vs Biosimilars: Product Redevelopment to Maintain a Competitive Market Advantage

In this article, Ross Errington, Head of Drug Product Development at Recipharm, explores the growth of the biosimilar market and its role in driving the demand for biologic redevelopment, focusing on the move towards inhaled biologics as a solution.

By PharmaManufacturing IQ Staff
Inhaled Biologics vs Biosimilars: Product Redevelopment to Maintain a Competitive Market Advantage
Published: | 4 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

Shutterstock

Only lasting approximately 20 years, the patents of many biologic blockbusters are nearing expiry in the next decade. As the cost of developing a biologic is around $800 million and the process can take an average of 8-10 years, originator companies are turning to drug product (DP) reformulation to maintain a competitive advantage.

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information